Parameningeal rhabdomyosarcoma

Results of an international workshop

Veronique Benk, C. Rodary, S. S. Donaldson, F. Flamant, Harold Maurice Maurer, I. Treuner, M. Carli, E. Gehan

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: A retrospective analysis was performed on children with nonmetastatic rhabdomyosarcomas (RMS) involving a parameningeal site treated by one of the four major cooperative groups: Intergroup Rhabdomyosarcoma Study (IRS), International Society of Pediatric Oncology (SLOP), German Cooperative Group (CWS), and Italian Cooperative Group (ICS) to analyse survival and prognostic factors. Methods and Materials: Between 1979 and 1989, 230 children (median age 6 years) were treated in the IRS III, SIOP 84, CWS81, and ICS 79 studies. All patients received chemotherapy, and 203 were irradiated. Radiotherapy doses were similar in the four studies, although treatment volumes were not similar. The SIOP patients had smaller volumes treated. In addition, the SIOP patients with a low risk of meningeal involvement and children under 5 years of age were not irradiated if they had a complete response (CR) to chemotherapy. Time to initiation of irradiation was earlier in the IRS and Italian studies. Results: Median follow-up was 62 months (range 22-140). The 5-year survival and 5-year event-free survival were better for the IRS study (74% and 71%) than for the other study groups (55% and 36% for SIOP, 47% and 47% for CWS, and 39% and 39% for ICS). The low-risk (LR) patients in the IRS study had improved survival. However, patients with high risk of meningeal involvement had similar survival in all four studies. The most significant prognostic factor was the size of tumor (>5 cm). Conclusion: The improved results from the IRS group, especially among the LR patients, could be related to the IRS treatment employed, particularly the systematic use of radiation, to the inclusion of patients with smaller tumors, and to the routine use of quality control of radiation.

Original languageEnglish (US)
Pages (from-to)533-540
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume36
Issue number3
DOIs
StatePublished - Oct 1 1996

Fingerprint

Rhabdomyosarcoma
Education
chemotherapy
tumors
Survival
Radiation
Drug Therapy
radiation
quality control
Survival Analysis
radiation therapy
Quality Control
Disease-Free Survival
Neoplasms
inclusions
Radiotherapy
dosage
Pediatrics
irradiation
Therapeutics

Keywords

  • Children
  • Radiation therapy
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Benk, V., Rodary, C., Donaldson, S. S., Flamant, F., Maurer, H. M., Treuner, I., ... Gehan, E. (1996). Parameningeal rhabdomyosarcoma: Results of an international workshop. International Journal of Radiation Oncology Biology Physics, 36(3), 533-540. https://doi.org/10.1016/S0360-3016(96)00362-8

Parameningeal rhabdomyosarcoma : Results of an international workshop. / Benk, Veronique; Rodary, C.; Donaldson, S. S.; Flamant, F.; Maurer, Harold Maurice; Treuner, I.; Carli, M.; Gehan, E.

In: International Journal of Radiation Oncology Biology Physics, Vol. 36, No. 3, 01.10.1996, p. 533-540.

Research output: Contribution to journalArticle

Benk, V, Rodary, C, Donaldson, SS, Flamant, F, Maurer, HM, Treuner, I, Carli, M & Gehan, E 1996, 'Parameningeal rhabdomyosarcoma: Results of an international workshop', International Journal of Radiation Oncology Biology Physics, vol. 36, no. 3, pp. 533-540. https://doi.org/10.1016/S0360-3016(96)00362-8
Benk, Veronique ; Rodary, C. ; Donaldson, S. S. ; Flamant, F. ; Maurer, Harold Maurice ; Treuner, I. ; Carli, M. ; Gehan, E. / Parameningeal rhabdomyosarcoma : Results of an international workshop. In: International Journal of Radiation Oncology Biology Physics. 1996 ; Vol. 36, No. 3. pp. 533-540.
@article{80a23976ffa849e392f3ab4d7dfbea34,
title = "Parameningeal rhabdomyosarcoma: Results of an international workshop",
abstract = "Purpose: A retrospective analysis was performed on children with nonmetastatic rhabdomyosarcomas (RMS) involving a parameningeal site treated by one of the four major cooperative groups: Intergroup Rhabdomyosarcoma Study (IRS), International Society of Pediatric Oncology (SLOP), German Cooperative Group (CWS), and Italian Cooperative Group (ICS) to analyse survival and prognostic factors. Methods and Materials: Between 1979 and 1989, 230 children (median age 6 years) were treated in the IRS III, SIOP 84, CWS81, and ICS 79 studies. All patients received chemotherapy, and 203 were irradiated. Radiotherapy doses were similar in the four studies, although treatment volumes were not similar. The SIOP patients had smaller volumes treated. In addition, the SIOP patients with a low risk of meningeal involvement and children under 5 years of age were not irradiated if they had a complete response (CR) to chemotherapy. Time to initiation of irradiation was earlier in the IRS and Italian studies. Results: Median follow-up was 62 months (range 22-140). The 5-year survival and 5-year event-free survival were better for the IRS study (74{\%} and 71{\%}) than for the other study groups (55{\%} and 36{\%} for SIOP, 47{\%} and 47{\%} for CWS, and 39{\%} and 39{\%} for ICS). The low-risk (LR) patients in the IRS study had improved survival. However, patients with high risk of meningeal involvement had similar survival in all four studies. The most significant prognostic factor was the size of tumor (>5 cm). Conclusion: The improved results from the IRS group, especially among the LR patients, could be related to the IRS treatment employed, particularly the systematic use of radiation, to the inclusion of patients with smaller tumors, and to the routine use of quality control of radiation.",
keywords = "Children, Radiation therapy, Rhabdomyosarcoma",
author = "Veronique Benk and C. Rodary and Donaldson, {S. S.} and F. Flamant and Maurer, {Harold Maurice} and I. Treuner and M. Carli and E. Gehan",
year = "1996",
month = "10",
day = "1",
doi = "10.1016/S0360-3016(96)00362-8",
language = "English (US)",
volume = "36",
pages = "533--540",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Parameningeal rhabdomyosarcoma

T2 - Results of an international workshop

AU - Benk, Veronique

AU - Rodary, C.

AU - Donaldson, S. S.

AU - Flamant, F.

AU - Maurer, Harold Maurice

AU - Treuner, I.

AU - Carli, M.

AU - Gehan, E.

PY - 1996/10/1

Y1 - 1996/10/1

N2 - Purpose: A retrospective analysis was performed on children with nonmetastatic rhabdomyosarcomas (RMS) involving a parameningeal site treated by one of the four major cooperative groups: Intergroup Rhabdomyosarcoma Study (IRS), International Society of Pediatric Oncology (SLOP), German Cooperative Group (CWS), and Italian Cooperative Group (ICS) to analyse survival and prognostic factors. Methods and Materials: Between 1979 and 1989, 230 children (median age 6 years) were treated in the IRS III, SIOP 84, CWS81, and ICS 79 studies. All patients received chemotherapy, and 203 were irradiated. Radiotherapy doses were similar in the four studies, although treatment volumes were not similar. The SIOP patients had smaller volumes treated. In addition, the SIOP patients with a low risk of meningeal involvement and children under 5 years of age were not irradiated if they had a complete response (CR) to chemotherapy. Time to initiation of irradiation was earlier in the IRS and Italian studies. Results: Median follow-up was 62 months (range 22-140). The 5-year survival and 5-year event-free survival were better for the IRS study (74% and 71%) than for the other study groups (55% and 36% for SIOP, 47% and 47% for CWS, and 39% and 39% for ICS). The low-risk (LR) patients in the IRS study had improved survival. However, patients with high risk of meningeal involvement had similar survival in all four studies. The most significant prognostic factor was the size of tumor (>5 cm). Conclusion: The improved results from the IRS group, especially among the LR patients, could be related to the IRS treatment employed, particularly the systematic use of radiation, to the inclusion of patients with smaller tumors, and to the routine use of quality control of radiation.

AB - Purpose: A retrospective analysis was performed on children with nonmetastatic rhabdomyosarcomas (RMS) involving a parameningeal site treated by one of the four major cooperative groups: Intergroup Rhabdomyosarcoma Study (IRS), International Society of Pediatric Oncology (SLOP), German Cooperative Group (CWS), and Italian Cooperative Group (ICS) to analyse survival and prognostic factors. Methods and Materials: Between 1979 and 1989, 230 children (median age 6 years) were treated in the IRS III, SIOP 84, CWS81, and ICS 79 studies. All patients received chemotherapy, and 203 were irradiated. Radiotherapy doses were similar in the four studies, although treatment volumes were not similar. The SIOP patients had smaller volumes treated. In addition, the SIOP patients with a low risk of meningeal involvement and children under 5 years of age were not irradiated if they had a complete response (CR) to chemotherapy. Time to initiation of irradiation was earlier in the IRS and Italian studies. Results: Median follow-up was 62 months (range 22-140). The 5-year survival and 5-year event-free survival were better for the IRS study (74% and 71%) than for the other study groups (55% and 36% for SIOP, 47% and 47% for CWS, and 39% and 39% for ICS). The low-risk (LR) patients in the IRS study had improved survival. However, patients with high risk of meningeal involvement had similar survival in all four studies. The most significant prognostic factor was the size of tumor (>5 cm). Conclusion: The improved results from the IRS group, especially among the LR patients, could be related to the IRS treatment employed, particularly the systematic use of radiation, to the inclusion of patients with smaller tumors, and to the routine use of quality control of radiation.

KW - Children

KW - Radiation therapy

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0030271741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030271741&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(96)00362-8

DO - 10.1016/S0360-3016(96)00362-8

M3 - Article

VL - 36

SP - 533

EP - 540

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -